Members of EAMG support the educational activities during the annual meeting of the European Academy of Allergy and Clinical Immunology with several symposia focusing on the potential and benefits of allergen specific immunotherapy. During symposia arranged by members of EAMG the latest products and treatment concepts for administration of allergen vaccines are discussed.

The following symposia are planned for the next EAACI meeting:

Sunday 7th June, 17:30
Satellite Symposium - ALK-Abelló

Innovative Approaches to Optimisation of Subcutaneous Immunotherapy

Chairperson:
Stephen Durham, United Kingdom

Understanding intact allergens - does nature know best?
Moises Calderon, United Kingdom

Understanding allergoids - improving on nature's design
Harald Renz, Germany

Understanding recombinant allergens - diagnosis and therapy of tomorrow?
Marianne van Hage, Sweden

Developments in specific immunotherapy - future directions and new opportunities
Henrik Jacobi, Denmark

Monday 8th June, 10:30
Company Sponsored Symposium  – Allergopharma
The Growing  Problem of Allergic Airway Disease - Aetiology and the Potential of Causal Treatment (SIT)

Chairpersons:
Marek Jutel, Poland
Gianni Marone, Italy

Allergic inflammation in the airways
Carsten Schmidt-Weber, United Kingdom

Modulation of allergic inflammation with specific immunotherapy
Sabina Rak, Sweden

Role of immunotherapy in asthma prevention and management
Christian Virchow, Germany

Aspects for therapeutic decisions in allergy
Gerard Schultze-Werninghaus, Germany

Monday 8th June, 10:30
Company Sponsored Symposium - ALK-Abellò
The management of united airways with tablet-based immunotherapy - evidence of curative effect?

Chairperson:
Glenis Scadding, United Kingdom

Allergic rhinitis is not a trivial disease - need for tablet-based immunotherapy?
Erkka Valovirta, Finland

Disease modifying effect of tablet-based immunotherapy - will this change our medical practice?
Stephen Durham, United Kingdom

House dust mite tablet-based immunotherapy in asthma - clinical proof of concept
Vibeke Backer, Germany

Does tablet-based immunotherapy address the needs of our patients?
Anthony Frew, United Kingdom

Tuesday 9th June, 10:30
Company Sponsored Symposium – Stallergenes
 Efficacy in SIT to Grass Pollen: the Meeting of "Evidence"

Chairpersons:
Karl-Christian Bergmann, Germany
Piotr Kuna, Poland

Pharmacodynamics of a sublingual desensitisation tablet: onset of action and clinical efficacy
Olivier de Beaumont, France

The grass pollen SLIT tablet: the EBM benchmark in SIT
Ulrich Wahn, Germany

SIT efficacy: evaluation of the therapeutic effect
Hans-Jørgen Malling, Denmark